Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KURA NASDAQ:MNMD NASDAQ:SANA NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.57+4.7%$7.61$5.41▼$19.73$830.65M0.321.78 million shs1.75 million shsMNMDMind Medicine (MindMed)$12.56+2.8%$9.83$4.70▼$12.76$955.66M2.551.70 million shs2.34 million shsSANASana Biotechnology$3.96-0.3%$3.43$1.26▼$7.30$941.71M1.913.70 million shs2.37 million shsSCLXScilex$15.78-9.0%$20.28$3.60▼$39.90$109.76M1.36294,576 shs507,226 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology0.00%+5.75%+17.71%+61.93%-48.27%MNMDMind Medicine (MindMed)0.00%+17.71%+36.08%+74.44%+126.31%SANASana Biotechnology0.00%+18.56%+32.89%+23.94%-9.17%SCLXScilex0.00%-45.98%-22.57%+163.00%-48.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKURAKura Oncology$9.57+4.7%$7.61$5.41▼$19.73$830.65M0.321.78 million shs1.75 million shsMNMDMind Medicine (MindMed)$12.56+2.8%$9.83$4.70▼$12.76$955.66M2.551.70 million shs2.34 million shsSANASana Biotechnology$3.96-0.3%$3.43$1.26▼$7.30$941.71M1.913.70 million shs2.37 million shsSCLXScilex$15.78-9.0%$20.28$3.60▼$39.90$109.76M1.36294,576 shs507,226 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKURAKura Oncology0.00%+5.75%+17.71%+61.93%-48.27%MNMDMind Medicine (MindMed)0.00%+17.71%+36.08%+74.44%+126.31%SANASana Biotechnology0.00%+18.56%+32.89%+23.94%-9.17%SCLXScilex0.00%-45.98%-22.57%+163.00%-48.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKURAKura Oncology 2.69Moderate Buy$24.10151.83% UpsideMNMDMind Medicine (MindMed) 3.00Buy$26.50110.99% UpsideSANASana Biotechnology 2.75Moderate Buy$7.5089.39% UpsideSCLXScilex 2.20Hold$455.002,783.40% UpsideCurrent Analyst Ratings BreakdownLatest SCLX, MNMD, SANA, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/27/2025KURAKura OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MNMDMind Medicine (MindMed)Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SANASana BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SCLXScilexWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025SANASana BiotechnologyWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.009/4/2025KURAKura OncologyGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral8/11/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$28.00 ➝ $24.008/4/2025MNMDMind Medicine (MindMed)OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.008/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKURAKura Oncology$53.88M15.42N/AN/A$5.32 per share1.80MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ASCLXScilex$56.59M1.94N/AN/A($27.68) per share-0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%11/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%11/6/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)SCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)Latest SCLX, MNMD, SANA, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKURAKura OncologyN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKURAKura Oncology0.026.166.16MNMDMind Medicine (MindMed)0.224.984.98SANASana BiotechnologyN/A2.472.47SCLXScilexN/A0.110.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKURAKura OncologyN/AMNMDMind Medicine (MindMed)27.91%SANASana Biotechnology88.23%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipKURAKura Oncology6.40%MNMDMind Medicine (MindMed)2.45%SANASana Biotechnology30.10%SCLXScilex7.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKURAKura Oncology13086.80 million81.24 millionOptionableMNMDMind Medicine (MindMed)4076.09 million74.22 millionOptionableSANASana Biotechnology380237.81 million166.23 millionOptionableSCLXScilex806.96 million6.40 millionNo DataSCLX, MNMD, SANA, and KURA HeadlinesRecent News About These CompaniesDatavault AI: The New AI Contender Backed by Big Funding (SCLX)...October 1, 2025 | marketbeat.comScilex Holding Company Enters Warrant Exercise AgreementOctober 1, 2025 | tipranks.comDatavault AI (NASDAQ: DVLT) Closes Initial Tranche of $150M Bitcoin Investment from Scilex HoldingOctober 1, 2025 | financial-news.co.ukScilex Holding Company Completes Repurchase of 3.13 Million Warrants from Oramed Pharmaceuticals for $13 MillionOctober 1, 2025 | quiverquant.comQScilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant RepurchaseOctober 1, 2025 | globenewswire.comScilex Holding Company $SCLX Shares Bought by Goldman Sachs Group Inc.October 1, 2025 | marketbeat.comDatavault AI: Fresh Capital, Blue-Chip Partnership Back A Speculative BuySeptember 30, 2025 | seekingalpha.comScilex Enters Crypto Market with $200M Bitcoin DealSeptember 26, 2025 | tipranks.comScilex Holding Company Updates Board After Business MergerSeptember 26, 2025 | tipranks.comScilex Invests $150 Million in Datavault AISeptember 26, 2025 | tipranks.comDatavault AI Announces Closing of Initial Tranche Investment from Scilex Holding CompanySeptember 26, 2025 | businesswire.comScilex Holding Company Completes Initial Tranche of $150 Million Investment in Datavault AI Inc.September 26, 2025 | quiverquant.comQScilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AISeptember 26, 2025 | globenewswire.comScilex to make $150M bitcoin investment in Datavault AISeptember 25, 2025 | msn.comScilex Holding Company Announces $150 Million Bitcoin Investment in Datavault AI Inc. to Accelerate Growth and InnovationSeptember 25, 2025 | quiverquant.comQScilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AISeptember 25, 2025 | globenewswire.comScilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of ...September 25, 2025 | finanznachrichten.deScilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in BitcoinSeptember 25, 2025 | globenewswire.comScilex enters MOU with Biconomy.com to collaborate on crypto strategySeptember 24, 2025 | msn.comScilex Holding Company Partners with Biconomy.com to Explore Cryptocurrency and Treasury Management StrategiesSeptember 24, 2025 | quiverquant.comQScilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury ManagementSeptember 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, MNMD, SANA, and KURA Company DescriptionsKura Oncology NASDAQ:KURA$9.57 +0.43 (+4.70%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.43 -0.14 (-1.46%) As of 10/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Mind Medicine (MindMed) NASDAQ:MNMD$12.56 +0.34 (+2.78%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$12.42 -0.15 (-1.15%) As of 10/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Sana Biotechnology NASDAQ:SANA$3.96 -0.01 (-0.25%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$4.05 +0.09 (+2.17%) As of 10/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Scilex NASDAQ:SCLX$15.78 -1.57 (-9.05%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.82 +0.04 (+0.22%) As of 10/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
